Tai Sandi See - Jan 7, 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Development Officer
Signature
/s/ Youjin Choi, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Jan 7, 2025
Transactions value $
$0
Form type
4
Date filed
1/10/2025, 04:55 PM
Previous filing
Feb 6, 2024
Next filing
Feb 21, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $0 +38.8K +233.08% $0.00 55.4K Jan 7, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (right to buy) Award $0 +77.5K $0.00 77.5K Jan 7, 2025 Common Stock 77.5K $7.33 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2 The reported securities are RSUs.
F3 25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.